GO
Loading...

Gilead Sciences Inc

More

  • Early Glance: Biotechnology companies Wednesday, 30 Jul 2014 | 10:42 AM ET

    Amgen Inc. rose $6.70 or 5.4 percent, to $130.01. Biogen Idec rose $4.40 or 1.3 percent, to $346.13. Celgene Corp. rose $1.63 or 1.9 percent, to $89.36.

  • July 30- U.S. health insurer Humana Inc said on Wednesday that second-quarter profit fell due to investments in the exchanges created under President Barack Obama's healthcare reform law as well as costly new hepatitis C drug treatments. Humana said membership growth and a lower share count due to stock buybacks had helped offset some of the new costs.

  • July 29- Aetna Inc, the third-largest U.S. health insurer, reported a rise in medical costs on Tuesday, raising investor concerns that a long run of low growth in such costs might be ending and pushing shares in the industry lower.

  • NEW YORK, July 29- With some of Wall Street's more volatile names set to report in the next couple of days, traders who bet on big swings in shares are hoping to see moves more like Facebook than Netflix. Netflix, along with Gilead Sciences and several other stocks famous for their sharp gyrations, were unusually calm following their latest quarterly reports.

  • $1,000 Sovaldi now hepatitis treatment of choice Tuesday, 29 Jul 2014 | 1:57 AM ET

    WASHINGTON— A $1,000- per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice for a liver-wasting viral disease that affects more than 3 million Americans. In less than six months, prescriptions for Sovaldi have eclipsed all other hepatitis C pills combined, according to new data from IMS Health.

  • Final Glance: Biotechnology companies Monday, 28 Jul 2014 | 6:04 PM ET

    Amgen Inc. fell$. 19 or. 2 percent, to $122.65. Biogen Idec rose$. 94 or. 3 percent, to $336.39. Celgene Corp. rose$. 48 or. 6 percent, to $87.64.

  • Midday Glance: Biotechnology companies Monday, 28 Jul 2014 | 1:31 PM ET

    Amgen Inc. fell$. 84 or. 7 percent, to $122.00. Biogen Idec fell$. 40 or. 1 percent, to $335.05. Celgene Corp. fell$. 19 or. 2 percent, to $86.97.

  • Early Glance: Biotechnology companies Monday, 28 Jul 2014 | 10:33 AM ET

    Amgen Inc. fell$. 67 or. 5 percent, to $122.17. Biogen Idec fell$. 97 or. 3 percent, to $334.48. Celgene Corp. fell$. 48 or. 6 percent, to $86.68.

  • Europe backs new leukemia drugs from J&J and Gilead Friday, 25 Jul 2014 | 7:20 AM ET

    LONDON, July 25- Two new leukemia drugs from Johnson& Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months. The European Medicines Agency said on Friday its experts had issued positive opinions for J&J's ibrutinib, developed with Pharmacyclics, and Gilead's idelalisib.

  • Final Glance: Biotechnology companies Thursday, 24 Jul 2014 | 6:22 PM ET

    Amgen Inc. rose$. 25 or. 2 percent, to $122.26. Biogen Idec fell$. 81 or. 2 percent, to $336.79. Celgene Corp. fell $2.93 or 3.3 percent, to $86.19.

  • Midday Glance: Biotechnology companies Thursday, 24 Jul 2014 | 1:23 PM ET

    Biogen Idec fell$. 94 or. 3 percent, to $336.66. Celgene Corp. fell $3.22 or 3.6 percent, to $85.90. Gilead Sciences Inc. rose$. 04 or percent, to $90.38.

  • Most active Nasdaq-traded stocks Thursday, 24 Jul 2014 | 1:23 PM ET

    Apple Inc. fell. 2 percent to $97.03 with 44,545,900 shares traded. Ariad Pharmaceuticals Inc. rose 5.2 percent to $6.18 with 26,030,200 shares traded. BlackBerry Ltd. rose 5.6 percent to $10.38 with 31,147,300 shares traded.

  • July 24- Celgene Corp reported a 25 percent rise in second-quarter profit, edging out Wall Street expectations, but a raised 2014 forecast failed to excite investors and its shares fell nearly 4 percent.

  • Early Glance: Biotechnology companies Thursday, 24 Jul 2014 | 11:37 AM ET

    Amgen Inc. fell$. 51 or. 4 percent, to $121.50. Biogen Idec rose$. 29 or. 1 percent, to $337.89. Celgene Corp. fell $3.63 or 4.1 percent, to $85.49.

  • July 23- Gilead Sciences Inc said on Wednesday that its new hepatitis C drug Sovaldi had sales of $3.5 billion in the second quarter, demonstrating that the furor over its price has not curtailed early use. Since its December launch, Sovaldi has been prescribed for more than 80,000 patients in the United States and Europe, the company said.

  • Aced the SAT? Try this Cramer question Wednesday, 23 Jul 2014 | 6:19 PM ET

    If you have a penchant for quizzes and such, Jim Cramer thinks this question could lead you to a solid stock idea.

  • After-hours buzz: Facebook, AT&T, Gilead & more Wednesday, 23 Jul 2014 | 5:15 PM ET
    A trader works on the floor of the New York Stock Exchange.

    Check out which companies are making headlines after the bell Wednesday: Facebook, AT&T, Gilead & more.

  • Gilead profit more than quadruples on hep C drug Wednesday, 23 Jul 2014 | 5:11 PM ET

    FOSTER CITY, Calif.— Gilead Sciences Inc. on Wednesday reported profit that more than quadrupled in its second quarter, topping analysts' expectations on sales of its new breakthrough drug for hepatitis C.

  • July 23- The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences Inc's Zydelig, a drug to treat three types of blood cancer. The FDA approved the use of Zydelig in combination with Roche AG's Rituxan for patients with relapsed chronic lymphocytic leukemia.

  • FDA approves Gilead Sciences drug for 3 cancers Wednesday, 23 Jul 2014 | 12:57 PM ET

    WASHINGTON— The Food and Drug Administration on Wednesday approved a new cancer drug from Gilead Sciences Inc. to treat three types of blood cancer. The FDA has approved three other drugs for the disease in the last year: Roche's Gazyva, Janssen Pharmaceutical's Imbruvica and GlaxoSmithKline's Arzerra.